Metraipolis › archive › dc_67aef7df3179
Development and Validation of an m6A-Derived Prognostic Signature in Lung Adenocarcinoma — Europe PMC PMID:42327582
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42327582
- DOI
- 10.7150/jca.134792
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-01T02:18:49.330Z
- SHA-256 of the archived text
e46d07e9ff90ba64d3bdec41174599ecf6dd3c3e5f7f416e2864f96cd6ca7351- Stable URL of this page
https://metraipolis.com/documento/dc_67aef7df3179
How to cite
Development and Validation of an m6A-Derived Prognostic Signature in Lung Adenocarcinoma — Europe PMC PMID:42327582 — Europe PMC (en), https://europepmc.org/article/MED/42327582 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_67aef7df3179 (Metraipolis archive dc_67aef7df3179, sha256 e46d07e9ff90ba64d3bdec41174599ecf6dd3c3e5f7f416e2864f96cd6ca7351)
BibTeX
@misc{dc67aef7df3179,
title = {Development and Validation of an m6A-Derived Prognostic Signature in Lung Adenocarcinoma — Europe PMC PMID:42327582},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42327582},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_67aef7df3179; sha256 e46d07e9ff90ba64d3bdec41174599ecf6dd3c3e5f7f416e2864f96cd6ca7351},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42327582. Agents can read the archived copy with the MCP tool read_document.